Drug class · Oncology & immunology
Kinase inhibitors Drug Codes & NDCs
Small-molecule drugs that inhibit one or more protein kinases. Most are oral products dispensed by pharmacies.
FDA-listed products
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Xeljanz XRtofacitinib | Tofacitinib citrate 11 mg/1 | Tablet, Extended releaseOral | U.S. Pharmaceuticals | 63539-501 |
| Xeljanz XRtofacitinib | Tofacitinib citrate 22 mg/1 | Tablet, Extended releaseOral | U.S. Pharmaceuticals | 63539-502 |
| Yulithiraeverolimus | Everolimus 2.5 mg/1 | TabletOral | CivicaScript, LLC | 82249-610 |
| Yulithiraeverolimus | Everolimus 5 mg/1 | TabletOral | CivicaScript, LLC | 82249-611 |
| Yulithiraeverolimus | Everolimus 7.5 mg/1 | TabletOral | CivicaScript, LLC | 82249-612 |
| Yulithiraeverolimus | Everolimus 10 mg/1 | TabletOral | CivicaScript, LLC | 82249-613 |
| Zelborafvemurafenib | Vemurafenib 240 mg/1 | Tablet, Film coatedOral | Genentech, Inc. | 50242-090 |
| Zortresseverolimus | Everolimus .5 mg/1 | TabletOral | Novartis Pharmaceuticals Corporation | 0078-0414 |
| Zortresseverolimus | Everolimus .75 mg/1 | TabletOral | Novartis Pharmaceuticals Corporation | 0078-0415 |
| Zortresseverolimus | Everolimus .25 mg/1 | TabletOral | Novartis Pharmaceuticals Corporation | 0078-0417 |
| Zortresseverolimus | Everolimus 1 mg/1 | TabletOral | Novartis Pharmaceuticals Corporation | 0078-0422 |
| Zydeligidelalisib | Idelalisib 100 mg/1 | Tablet, Film coatedOral | Gilead Sciences, Inc. | 61958-1701 |
| Zydeligidelalisib | Idelalisib 150 mg/1 | Tablet, Film coatedOral | Gilead Sciences, Inc. | 61958-1702 |
| Zykadiaceritinib | Ceritinib 150 mg/1 | Tablet, Film coatedOral | Novartis Pharmaceuticals Corporation | 0078-0694 |